Pharming (PHAR) Gross Profit (2020 - 2026)

Pharming's Gross Profit history runs 7 years deep, the most recent figure standing at $65.8 million for Q1 2026.

• Quarterly Gross Profit rose 92980075.5% year-over-year to $65.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $156.0 million (up 37.68% YoY) and the FY2025 annual result came in at $330.6 million, up 26.29% from the prior year.
• Gross Profit was $65.8 million for Q1 2026 at Pharming, up from $85.4 in the prior quarter.
• Across five years, Gross Profit topped out at $146000.0 billion in Q4 2023 and bottomed at $47.2 in Q1 2024.
• A 5-year average of $11482.4 billion and a median of $46.1 million in 2022 frame the typical range for Gross Profit.
• Annual changes were most pronounced in 2024 — Gross Profit slumped 100.0% — and 2025, when it surged 132646958.82%.
• Pharming's Gross Profit stood at $139.7 million in 2022, then jumped by 104509563.56% to $146000.0 billion in 2023, then slumped by 100.0% to $181.3 in 2024, then plunged by 52.9% to $85.4 in 2025, then jumped by 77052593.21% to $65.8 million in 2026.
• Business Quant data shows PHAR's Gross Profit at $65.8 million in Q1 2026, $85.4 in Q4 2025, and $90.2 million in Q3 2025.